The PI3K-AKT pathway has been reported to be activated in NSCLC, and some small compound inhibitors of PI3K and AKT were developed for clinical trials in NSCLC patients (Tan, 2020). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.